Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04942964 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04942964 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 25 participants.
The verdict
NCT04942964, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function. The study will also evaluate the safety and tolerability of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function.
Interventions
- DRUG Bocidelpar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04942964
The ClinicalTrials.gov registry entry for NCT04942964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bocidelpar is the first listed.
NCT04942964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04942964 about?
NCT04942964 is a clinical study titled "A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function". The purpose of this study is to evaluate the effect of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function. The study will also evaluate the safety and tolerability of ASP0367 in participants with mild and moderate hepatic i...
What is the current status of trial NCT04942964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-09-13. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT04942964?
The interventions under investigation include: Bocidelpar (DRUG).
Who is sponsoring clinical trial NCT04942964?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.